CA3245204A1 - HETEROCYCLIC DERIVATIVES WITH MEDIUM OR MACROCYCLIC BENZYL SUBSTITUTION AND ASSOCIATED USES - Google Patents

HETEROCYCLIC DERIVATIVES WITH MEDIUM OR MACROCYCLIC BENZYL SUBSTITUTION AND ASSOCIATED USES

Info

Publication number
CA3245204A1
CA3245204A1 CA3245204A CA3245204A CA3245204A1 CA 3245204 A1 CA3245204 A1 CA 3245204A1 CA 3245204 A CA3245204 A CA 3245204A CA 3245204 A CA3245204 A CA 3245204A CA 3245204 A1 CA3245204 A1 CA 3245204A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
halogen
pharmaceutically acceptable
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3245204A
Other languages
English (en)
French (fr)
Inventor
Gregory R. Ott
Karl GIBSON
Bruce Lefker
Paul Humphries
Matthew SPENDIFF
Original Assignee
Centessa Pharmaceuticals UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centessa Pharmaceuticals UK Ltd filed Critical Centessa Pharmaceuticals UK Ltd
Publication of CA3245204A1 publication Critical patent/CA3245204A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3245204A 2022-03-01 2023-03-01 HETEROCYCLIC DERIVATIVES WITH MEDIUM OR MACROCYCLIC BENZYL SUBSTITUTION AND ASSOCIATED USES Pending CA3245204A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263315438P 2022-03-01 2022-03-01
US63/315,438 2022-03-01
US202363439477P 2023-01-17 2023-01-17
US63/439,477 2023-01-17
PCT/US2023/014275 WO2023167925A1 (en) 2022-03-01 2023-03-01 Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses

Publications (1)

Publication Number Publication Date
CA3245204A1 true CA3245204A1 (en) 2023-09-07

Family

ID=85772026

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3245204A Pending CA3245204A1 (en) 2022-03-01 2023-03-01 HETEROCYCLIC DERIVATIVES WITH MEDIUM OR MACROCYCLIC BENZYL SUBSTITUTION AND ASSOCIATED USES

Country Status (12)

Country Link
US (2) US20250236629A1 (https=)
EP (1) EP4486748A1 (https=)
JP (1) JP2025507852A (https=)
KR (1) KR20240157067A (https=)
CN (1) CN119110802A (https=)
AU (1) AU2023228830A1 (https=)
CA (1) CA3245204A1 (https=)
CL (1) CL2024002576A1 (https=)
IL (1) IL315237A (https=)
MX (1) MX2024010608A (https=)
TW (1) TW202400606A (https=)
WO (1) WO2023167925A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
KR20250155550A (ko) 2023-03-16 2025-10-30 다케다 야쿠힌 고교 가부시키가이샤 매크로시클릭 헤테로시클 화합물 및 이의 용도
US20240425521A1 (en) 2023-06-01 2024-12-26 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20200207734A1 (en) 2017-08-03 2020-07-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
SG11202106791XA (en) 2019-01-31 2021-07-29 Takeda Pharmaceuticals Co Heterocyclic compound and use thereof
FI4065585T3 (fi) * 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
WO2022051583A1 (en) * 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists

Also Published As

Publication number Publication date
CN119110802A (zh) 2024-12-10
US20250289828A1 (en) 2025-09-18
CL2024002576A1 (es) 2025-01-10
TW202400606A (zh) 2024-01-01
US20250236629A1 (en) 2025-07-24
JP2025507852A (ja) 2025-03-21
IL315237A (en) 2024-10-01
EP4486748A1 (en) 2025-01-08
WO2023167925A1 (en) 2023-09-07
MX2024010608A (es) 2024-09-23
AU2023228830A1 (en) 2024-09-12
KR20240157067A (ko) 2024-10-31

Similar Documents

Publication Publication Date Title
US12503475B2 (en) Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
EP4208465A1 (en) Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
CA3245204A1 (en) HETEROCYCLIC DERIVATIVES WITH MEDIUM OR MACROCYCLIC BENZYL SUBSTITUTION AND ASSOCIATED USES
CA2975605C (en) 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
IL275058B2 (en) Sulfonylurea derivatives as modulators of the NLRP3 inflammasome
WO2025072451A1 (en) Ras-pi3k inhibitors for the treatment of cancer and immunological diseases
TW201734001A (zh) ＲＯＲ－γ調節劑
EP4486445A1 (en) Bicyclic-heterocycle derivatives and related uses
WO2022207935A1 (en) 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
WO2021170627A1 (en) Difluorocyclohexyl derivatives as il-17 modulators
CA2944256A1 (en) 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
TW202233620A (zh) Cftr調節劑化合物、組合物及其用途
US20240083872A1 (en) Cyclic amine derivatives having serotonin receptor binding activity
AU2019223882B2 (en) Receptor inhibitors, pharmaceutical compositions comprising the same, and usage thereof
JP2025521507A (ja) 置換縮合二環式化合物および関連する治療方法
CA3180417A1 (en) Synthesis of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid
EA052303B1 (ru) Средне- или макроциклические производные бензилзамещенного гетероцикла и связанные с ними применения
TW202530205A (zh) 經取代之芳基磺醯胺及其組合物及用途
TW202537962A (zh) 抑制α-V β-1整合素
WO2025211975A1 (en) Orexin receptor agonists
KR20260012686A (ko) 신규한 오렉신 2 수용체 작용제 및 이의 용도
KR20260005897A (ko) 신규 화합물 및 이의 용도
HK1228903A1 (en) 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240828

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240829

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240829

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240829

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250212

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321